Life Sciences and Healthcare in focus Find out more EN Search Menu Life Sciences and Healthcare Industries making an impact on modern society Life sciences, health and social care are vitally important in the development of modern society, with a diverse range of stakeholders, from the general public and clinical practitioners to regulators, insurers and governments. We understand the unique challenges of the industry and deliver results-focused advice for a diverse range of clients, from drug developers to healthcare providers and the entities that finance and support them. Breadcrumb Home Our core sectors Life Sciences and Healthcare Our focus areas Biotech and pharmaceuticals In life sciences, we have a strong track record in domestic and cross-border mergers and acquisitions, helping our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing IP and tax advice. Learn more Digital health Our specialist healthcare technology practice advises the companies and investors that are transforming the way therapies and patient services are delivered. Learn more Healthcare In health and social care, we advise on everything from the building and operating of hospitals and care homes to the provision of new methods of diagnosis and treatment. Learn more Our Experience Bone Therapeutics Advised Bone Therapeutics, addressing high unmet medical needs in orthopaedics and bone diseases, on its €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation. Read more here > NeRRe Therapeutics Advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. Read more here > Grifols Advised global healthcare leader, Grifols on a ~USD 1 billion strategic investment from Singapore’s sovereign wealth fund. Read more here > Amphista Therapeutics Advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round. Read more. Grifols Advised Grifols on its strategic alliance and investment in Shanghai RAAS. LDC Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m. Univercells Advised on a series A investment in Belgian biotech company Univercells. Healthcare provider Advised a digital primary care healthcare provider on EU and UK health and data regulations, preparing global contracting documentation and insurance advice. Previous Next 1 2 3 Life Sciences and Healthcare: In focus Our ever-growing hub of life sciences and healthcare insight: up-to-the-second industry news, information on data, medical research and pharmaceutical innovation, and, most importantly, their legal implications and practical guidance on applying the knowledge you gain. Explore Insights Intellectual property Supreme Court gives certainty to patentees in unlawful means economic tort claims The Supreme Court's decision in Secretary of State for Health and another v Servier Laboratories Ltd and others is welcome... 09/11/2021 COP26 COP26 | Energy Day Yesterday was Finance Day where delegates discussed how to accelerate the mobilisation of public and private finance for climate action... 04/11/2021 Sustainable disruption: 12 decarbonising technologies for cities Can sustainable disruption and technology deliver decarbonised cities? Technology has a crucial role in helping consumers, businesses and organisations meet their climate change objectives, and cities and urban... 02/11/2021 View all insights Connect with one of our experts Silvia Steiner Partner, International Head of Life Sciences and Healthcare, Spain +34 93 419 18 18 Email Silvia Full biog Find your local Life Sciences and Healthcare experts Location Belgium Germany France UK India Italy The Netherlands Sweden Spain US News and deals Osborne Clarke advises Sanity Group on Snoop Dogg's Casa Verde investment Published on 15/11/2021 Osborne Clarke advises Tiger Global on its lead investment in Lifebit's $60M series B round Published on 29/09/2021 Osborne Clarke advises Grifols on EUR1.1bn Biotest acquisition Published on 24/09/2021 Osborne Clarke welcomes Valentin de le Court to strengthen its industrial property law practice and expand its IP/IT/Data team in Brussels. Published on 23/09/2021 Read time 3m Osborne Clarke advises Creo Medical Group on £36M fundraising Published on 07/09/2021 Previous Next 1 2 3 4 5 6 7 8 9 View all news Explore Lawyers Sectors Transformation Services Insights Events Locations Useful links Site map Terms and conditions Contact us Privacy policy California Privacy Notice Slavery statement Alumni Cookie policy Transparency Sign up for our newsletter Register now for more insights, news and events from across Osborne Clarke from across Osborne Clarke. Sign up Follow us Legal Notice When you read about Osborne Clarke on this site, we are either referring to our international organisation, Osborne Clarke Verein (OCV), or one of its member firms. OCV is a Swiss verein and doesn’t provide services to clients. The OCV member firms are all separate legal entities and have no authority to obligate or bind each other or OCV with regard to third parties. To find out more, please click here. Some are not essential but help to improve our website and your experience. You can choose which optional cookies to allow using the Cookies Manager button below. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Using this tool will set a cookie on your device to remember your preferences.For more detailed information about the cookies we use, see our cookies policy Reject all cookies Accept all cookies Cookies Manager